PhRMA lies to protect pharma profits
World of DTC Marketing
AUGUST 12, 2022
Data were mainly accessible for smaller firms, products in some therapeutic regions, orphan drugs, first-in-class drugs, therapeutic agents that received accelerated approval, and products between 2014 and 2018. The most telling data on a disconnect between drug prices and research costs has received almost no public attention.
Let's personalize your content